Effect of administering Intralipid drug during the bypass in Patients Undergoing Off-Pump Coronary Artery Bypass Surgery

Effect of Peri-conditioning with intralipid in Patients Undergoing Off-Pump Coronary Artery Bypass Surgery - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/01/079208

Enrollment

Registered

2025-01-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I21- Acute myocardial infarction Health Condition 2: I25- Chronic ischemic heart disease Health Condition 3: I20-I25- Ischemic heart diseases

Interventions

Intervention1: Intralipid Infusion: Infusion of 20% Intralipid 2ml/kg from the start of Left Internal Mammary Artery harvesting till the end of grafting over a period of 90 minutes Control Interventio

Eligibility

Inclusion criteria

Inclusion criteria: Patients posted for elective Off Pump Coronary Artery Bypass Surgery (OPCAB) with left ventricular ejection fraction (LVEF) more than 40 percentage.

Exclusion criteria

Exclusion criteria: Combined valve and coronary surgery, on-pump CABG, redo cardiac surgery, hyperlipidaemia, significant hepatic or renal dysfunction, uncontrolled hypertension, diabetes mellitus, any disorder with immunological dysfunction (like malignancy or positive serological test for the HIV) in the last 6 months, preoperative treatment with nicorandil (an ATP-sensitive potassium channel opener), sulfonylurea (an ATP- sensitive potassium channel blocker).

Design outcomes

Primary

Measure	Time frame
To evaluate the cardioprotective role of Intralipid (IL) by assessing Troponin ITimepoint: postoperatively 6th hourly, 24th hourly, 48th hourly and 72nd hourly	—

Secondary

Measure	Time frame
to find out the hemodynamic effect of intralipid on systemic circulationTimepoint: intraoperatively initiating intralipid infusion at 0 min, 1 min, 5 min, 10 min, 15 min, 20min, 25 min, 30 min and postoperatively after shifting;to estimate the clinical effect of inotropic useTimepoint: intraoperatively, POD-1 and POD-2;LVEFTimepoint: at the time of discharge;to find out the effect of intralipid on the serum levels of blood lipids, serum creatinine and total bilirubinTimepoint: pre-operatively, post-operatively POD1 and POD2;to find out the effect of intralipid on the ventilatory hours and length of ICU stay post-operativelyTimepoint: Post-operative period;to find out the outcome on the complications occuring during hospitalisation including arrhythmias, stroke, infection, respiratory failure, hepatic or renal failure, reoperation and mortality will be notedTimepoint: intraoperative and postoperative period	—

Measure

Time frame

to find out the hemodynamic effect of intralipid on systemic circulationTimepoint: intraoperatively initiating intralipid infusion at 0 min, 1 min, 5 min, 10 min, 15 min, 20min, 25 min, 30 min and postoperatively after shifting;to estimate the clinical effect of inotropic useTimepoint: intraoperatively, POD-1 and POD-2;LVEFTimepoint: at the time of discharge;to find out the effect of intralipid on the serum levels of blood lipids, serum creatinine and total bilirubinTimepoint: pre-operatively, post-operatively POD1 and POD2;to find out the effect of intralipid on the ventilatory hours and length of ICU stay post-operativelyTimepoint: Post-operative period;to find out the outcome on the complications occuring during hospitalisation including arrhythmias, stroke, infection, respiratory failure, hepatic or renal failure, reoperation and mortality will be notedTimepoint: intraoperative and postoperative period

—

Countries

India

Contacts

Public ContactDr Gegal Pruthi

All India Institute of Medical Sciences, Bathinda

drpkc12@gmail.com8558038098

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026